{"id":36394,"date":"2019-07-24T15:52:54","date_gmt":"2019-07-24T15:52:54","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=36394"},"modified":"2019-12-06T09:59:08","modified_gmt":"2019-12-06T09:59:08","slug":"first-reports-from-ias-2019","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/36394","title":{"rendered":"10th IAS Conference on HIV Science (IAS 2019) in Mexico City"},"content":{"rendered":"<p><b><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-36338\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2019\/07\/IAS-2019-web-logo-text-176x300.png\" alt=\"\" width=\"176\" height=\"300\" srcset=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2019\/07\/IAS-2019-web-logo-text-176x300.png 176w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2019\/07\/IAS-2019-web-logo-text.png 237w\" sizes=\"auto, (max-width: 176px) 100vw, 176px\" \/>Simon\u00a0Collins,\u00a0HIV\u00a0i-Base<\/b><\/p>\n<p><strong>The 10th IAS Conference on HIV Science (IAS 2019) in Mexico City was held from 21 \u2013 24 July 2019.<\/strong><\/p>\n<p>The meeting included more than 5,000 participants from more than 140 countries.<\/p>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">This year the meeting had a particulaly exciting programme,:<\/span><\/p>\n<ul>\n<li class=\"HTBBODYtext\"><span lang=\"EN-US\">A strong focus on new antiretroviral drugs, including for PrEP.<\/span><\/li>\n<li class=\"HTBBODYtext\"><span lang=\"EN-US\">ART strategies with new and existing drugs.<\/span><\/li>\n<li class=\"HTBBODYtext\"><span lang=\"EN-US\">An important (and optimistic) update on neural tube defects with dolutegravir, with a comprehensive review of the latest data.<\/span><\/li>\n<li class=\"HTBBODYtext\"><span lang=\"EN-US\">Updates to WHO treatment guidelines<\/span><\/li>\n<\/ul>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">The programme is already posted online, with abstracts and PowerPoint slides available for many of the presentations.<\/span><\/p>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\"><a href=\"http:\/\/www.ias2019.org\/\" rel=\"noopener noreferrer\">http:\/\/www.ias2019.org\u00a0<\/a><\/span><\/p>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">Webcasts from oral presentations, including the opening sessions are posted to the conference YouTube channel.<br \/>\n<a href=\"https:\/\/www.youtube.com\/channel\/UC43XbxjX7RZZ_gK9Vt8Z8FA\/videos\" rel=\"noopener noreferrer\">https:\/\/www.youtube.com\/channel\/UC43XbxjX7RZZ_gK9Vt8Z8FA\/videos<\/a><\/span><\/p>\n<p>Early HTB reports will be posted below as soon as they are available.<\/p>\n<p>These include:<\/p>\n<ul>\n<li><a href=\"https:\/\/i-base.info\/htb\/36478\" rel=\"noopener noreferrer\">Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/36402\">WHO recommends dolutegravir-based ART regimens for all<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/36483\" rel=\"noopener noreferrer\">High rates of viral suppression with low dose efavirenz in pregnant Zambian women<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/36437\" rel=\"noopener noreferrer\">Dolutegravir\/lamivudine dual therapy non-inferior to triple ART at week-96<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/36450\" rel=\"noopener noreferrer\">Switching to dolutegravir\/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/36443\" rel=\"noopener noreferrer\">Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/36383\" rel=\"noopener noreferrer\">First viral load results for capsid inhibitor GS-6207: mean \u20132.2 log reduction at day 10<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/36398\" rel=\"noopener noreferrer\">Islatravir (MK-8591) in new fixed dose combination (FDC) with doravirine plus lamivudine: 24 week results<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/36390\">Fostemsavir: 96-week follow-up in people with multi-drug resistance<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/36419\" rel=\"noopener noreferrer\">Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/36341\">IAS\u00a02019:\u00a0late\u00a0breaker\u00a0highlights<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>First ten reports from IAS 2019&#8230;<\/p>\n","protected":false},"author":3,"featured_media":36493,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[12,273],"class_list":["post-36394","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-conference-reports","tag-conference-index","tag-ias-10-mexico-city-2019"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/36394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=36394"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/36394\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media\/36493"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=36394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=36394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=36394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}